Prophylactic cranial irradiation (PCI) is considered an important technological advance made in oncology in an effort to reduce the incidence of brain metastases (BM) and improve overall survival (OS) of patients with small cell lung cancer (SCLC). Although it is often reported that PCI improves the therapeutic potential in limited-stage (LS) SCLC, no randomised trial has ever conclusively confirmed this. Nevertheless, PCI has been considered the standard of care for LS-SCLC since the late 1990s. The data supporting the use of PCI in LS-SCLC are based on an analysis of work performed prior to the current approach to staging [brain magnetic resonance imaging (MRI), positron emission tomography (PET)/computed tomography (CT)]. The evidence for the rationale and feasibility of this approach in the modern diagnostic era should be demonstrated. The situation with extensive stage (ES) SCLC is seemingly easier because, unlike LS-SCLC, we have data from two randomised trials. Unfortunately, their results are in direct conflict with each other. Although it is generally assumed that good control of brain disease leads to better quality of life, this has never been prospectively demonstrated. In fact, PCI is associated not only with increased treatment costs and some patient discomfort, but also with non-negligible potential toxicity. For this reason, efforts have been made to preserve cognitive function by sparing the hippocampus. This concept is called hippocampal avoidance. The optimal fractionation regimen is currently less controversial than the optimal integration of PCI into the treatment algorithm. A dose of 25 Gy administered in 10 fractions should remain the standard for the eventual use of PCI in patients with SCLC. In summary, PCI is not a conditio sine qua non in any indication. Neither in patients with LS-SCLC nor in patients with ES-SCLC has a clear improvement in OS been demonstrated at follow-up using current imaging modalities.

Department of Oncology and Radiotherapy University Hospital in Pilsen Czech Republic

Zobrazit více v PubMed

Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 2000;18(19):3400–3408. doi: 10.1200/JCO.2000.18.19.3400. PubMed DOI

Hochstenbag MMH, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003;42(2):189–193. doi: 10.1016/s0169-5002(03)00291-5. PubMed DOI

van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755. doi: 10.1016/S0140-6736(11)60165-7. PubMed DOI

Jackson D. Prophylactic Cranial Irradiation in Small Cell Carcinoma of the Lung. JAMA. 1977;237(25):2730. doi: 10.1001/jama.1977.03270520040019. PubMed DOI

Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–484. doi: 10.1056/NEJM199908123410703. PubMed DOI

Edelman MJ. Prophylactic Cranial Irradiation for Small-Cell Lung Cancer: Time for a Reassessment. Am Soc Clin Oncol Educ Book. 2020;40:24–28. doi: 10.1200/EDBK_281041. PubMed DOI

Arriagada R, Le Chevalier T, Rivière A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol. 2002;13(5):748–754. doi: 10.1093/annonc/mdf123. PubMed DOI

Seute T, Leffers P, ten Velde GPM, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI) Cancer. 2008;112(8):1827–1834. doi: 10.1002/cncr.23361. PubMed DOI

Xu J, Yang H, Fu X, et al. Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):347–353. doi: 10.1016/j.jtho.2016.09.133. PubMed DOI

Slotman B, Faivre-Finn C, Kramer G, et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–672. doi: 10.1056/NEJ-Moa071780. PubMed DOI

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8–15. doi: 10.1054/bjoc.2000.1164. PubMed DOI PMC

Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–671. doi: 10.1016/S1470-2045(17)30230-9. PubMed DOI

Maeng CH, Song JU, Shim SR, et al. The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2018;13(6):840–848. doi: 10.1016/j.jtho.2018.02.024. PubMed DOI

SWOG S. (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer. 1827. https://clinicaltrials.gov/ct2/show/NCT04155034 .

Lok BH, Ma J, Foster A, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Adv Radiat Oncol. 2017;2(4):548–554. doi: 10.1016/j.adro.2017.08.001. PubMed DOI PMC

Chang EL, Wefel JS, Hess KR, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60(2):277–83. doi: 10.1227/01.NEU.0000249272.64439.B1. discussion 283. PubMed DOI

Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348–354. doi: 10.1016/j.ijrobp.2012.11.031. PubMed DOI

Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316(4):401–409. doi: 10.1001/jama.2016.9839. PubMed DOI PMC

Rodríguez de Dios N, Couñago F, Murcia-Mejía M, et al. Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/ Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group. Clin Lung Cancer. 2018;19(5):e693–e697. doi: 10.1016/j.cllc.2018.05.003. PubMed DOI

Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–286. doi: 10.1200/JCO.2010.29.6053. PubMed DOI PMC

Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29(3):272–278. doi: 10.1200/JCO.2010.29.1609. PubMed DOI PMC

Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84. doi: 10.1016/j.ijrobp.2010.05.013. PubMed DOI PMC

Gondi V, Paulus R, Bruner DW, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656–664. doi: 10.1016/j.ijrobp.2013.02.033. PubMed DOI PMC

Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–3816. doi: 10.1200/JCO.2014.57.2909. PubMed DOI PMC

Kundapur V, Ellchuk T, Ahmed S, et al. Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation. Int J Radiat Oncol Biol Phys. 2015;91(4):781–786. doi: 10.1016/j.ijrobp.2014.12.026. PubMed DOI

Cook TA, Hoffmann MR, Ross AJ, et al. Patterns of relapse following hippocampal avoidance prophylactic cranial irradiation for small cell lung carcinoma. Rep Pract Oncol Radiother. 2021;26(6):968–975. doi: 10.5603/RPOR.a2021.0119. PubMed DOI PMC

Rodríguez de Dios N, Couñago F, Murcia-Mejía M, et al. Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/ Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group. Clin Lung Cancer. 2018;19(5):e693–e697. doi: 10.1016/j.cllc.2018.05.003. PubMed DOI

Albers EAC, Zeng H, De Ruysscher DKM, et al. Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675) J Thorac Oncol. 2021;16(5):840–849. doi: 10.1016/j.jtho.2020.12.024. PubMed DOI

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT02635009 .

Brown PD, Pugh S, Laack NN, et al. Radiation Therapy Oncology Group (RTOG) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429–1437. doi: 10.1093/neuonc/not114. PubMed DOI PMC

Brown PD, Gondi V, Pugh S, et al. for NRG Oncology. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019–1029. doi: 10.1200/JCO.19.02767. PubMed DOI PMC

Le Péchoux C, Dunant A, Senan S, et al. Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–474. doi: 10.1016/S1470-2045(09)70101-9. PubMed DOI

Kamath SD, Kumthekar PU. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. Front Oncol. 2018;8:414. doi: 10.3389/fonc.2018.00414. PubMed DOI PMC

Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. doi: 10.1056/NEJMoa1709937. PubMed DOI

Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators, CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi: 10.1016/S0140-6736(19)32222-6. PubMed DOI

Salama JK, Gu L, Wang X, et al. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE) J Thorac Oncol. 2016;11(3):361–369. doi: 10.1016/j.jtho.2015.11.001. PubMed DOI PMC

Xue S, Zeng H, Yan S, et al. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Controversial Area. Front Oncol. 2022;12:772282. doi: 10.3389/fonc.2022.772282. PubMed DOI PMC

NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 3, 2023. 2022 December 21; PubMed

Dingemans AMC, Früh M, Ardizzoni A, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839–853. doi: 10.1016/j.annonc.2021.03.207. PubMed DOI PMC

Le Rhun E, Guckenberger M, Smits M, et al. EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332–1347. doi: 10.1016/j.annonc.2021.07.016. PubMed DOI